Group One Trading’s Atrium Therapeutics RNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$175K Sell
21,100
-5,200
-20% -$61.3K ﹤0.01% 4285
2026
Q2
$354K Hold
26,300
– – ﹤0.01% 3819
2026
Q1
$352K Buy
+26,300
New +$370K ﹤0.01% 3660

Other funds holding RNA

Group One Trading's RNA Position: Q3 2026 in Review

Group One Trading reduced its Atrium Therapeutics (RNA) stake by 98% in Q3 2026, selling an estimated $41.2K and leaving 85 shares worth $704. The position accounts for ﹤0.01% of the portfolio, ranked #7213.

Group One Trading first reported a position in RNA in Q1 2026 and has held it in 3 quarters since. The position peaked at $49.2K in Q1 2026. 148 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Group One Trading held 85 shares of Atrium Therapeutics worth $704 as of Q3 2026.
  • Group One Trading sold 3,490 Atrium Therapeutics shares in Q3 2026, an estimated $41.2K.
  • Atrium Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q3 2026, its #7213 holding.
  • Group One Trading first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Group One Trading's Atrium Therapeutics position peaked at $49.2K in Q1 2026.
  • 148 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Group One Trading's 13F filing for Q3 2026, filed 10 Nov 2026.